ArticleCurrent neurology and neuroscience reports2016
Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.
Article in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.The Cochrane database of systematic reviews · 2020Pooled it
- Article
- T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas.Future oncology (London, England) · 2024Article
- Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery.Frontiers in surgery · 2022Article
- Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas.Frontiers in neuroscience · 2022Review
- Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients?Diagnostic and interventional radiology (Ankara, Turkey) · 2021Article
- Predicting factors of tumor progression in adult patients with low-grade glioma within five years after surgery.Translational cancer research · 2021Article
- Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.Cancer medicine · 2020Review
- Dysregulated Expression and Methylation Analysis IdentifiedInternational journal of genomics · 2020Article
- Integrated systems-genetic analyses reveal a network target for delaying glioma progression.Annals of clinical and translational neurology · 2019Article
- Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.PLoS medicine · 2019Observational
- Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas.Translational oncology · 2018Article
- MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.AJR. American journal of roentgenology · 2018Article
- Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.Neuroradiology · 2018Article
- Current Clinical Brain Tumor Imaging.Neurosurgery · 2017Review
- Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- Multiple-response regression analysis links magnetic resonance imaging features to de-regulated protein expression and pathway activity in lower grade glioma.Oncoscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse infiltrative low grade gliomas (LGG) account for approximately 15 % of all gliomas. The prognosis of LGG differs between high-risk and low-risk patients notwithstanding varying definitions of what constitutes a high-risk patient. Maximal safe resection optimally is the initial treatment. Surgery that achieves a large volume resection improves both progression-free and overall survival. Based on results of three randomized clinical trials (RCT), radiotherapy (RT) may be deferred in patients with low-risk LGG (defined as age <40 years and having undergone a complete resection), although combined chemoradiotherapy has never been prospectively evaluated in the low-risk population. The recent RTOG 9802 RCT established a new standard of care in high-risk patients (defined as age >40 years or incomplete resection) by demonstrating a nearly twofold improvement in overall survival with the addition of PCV (procarbazine, CCNU, vincristine) chemotherapy following RT as compared to RT alone. Chemotherapy alone as a treatment of LGG may result in less toxicity than RT; however, this has only been prospectively studied once (EORTC 22033) in high-risk patients. A challenge remains to define when an aggressive treatment improves survival without impacting quality of life (QoL) or neurocognitive function and when an effective treatment can be delayed in order to preserve QoL without impacting survival. Current WHO histopathological classification is poorly predictive of outcome in patients with LGG. The integration of molecular biomarkers with histology will lead to an improved classification that more accurately reflects underlying tumor biology, prognosis, and hopefully best therapy.
Indexed as
Identifiers
26750130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.